Promising drug cocktail eyed for Tough-to-Treat urinary cancer
NCT ID NCT07633353
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how well a combination of two drugs (enfortumab vedotin and pembrolizumab) works as a first treatment for people with advanced upper tract urothelial carcinoma, a rare cancer of the urinary tract. Researchers will track 50 patients in France to see how many respond to treatment and how long they live without the cancer growing. They will also check for side effects and look at certain markers in the tumors that might predict who benefits most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
enfortumab vedotin plus pembrolizumab
What this could lead to
If successful, this could confirm that the drug combination is an effective first-line treatment for this rare type of urinary tract cancer.
What could go wrong
This is a small, observational study (50 patients) with no control group, so results may not be definitive. Side effects from the drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UPPER TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Universitaire
Nîmes, 30000, France